|
Ahead of the Bell: Helicos BioSciences Thursday July 5, 9:35 am ET Helicos Rated 'Neutral' As Analysts Expect Strong Competition for Gene Sequencing Products NEW YORK (AP) -- A pair of analysts initiated coverage of Helicos BioSciences Corp. with "Neutral" ratings Thursday, praising the company's technology but warning it will face stiff competition. Helicos develops genetic testing methods that can be used in research, drug testing or diagnosing diseases. JPMorgan analyst Tycho W. Peterson began covering the stock with a "Neutral" rating. He said the company has developed a genetic sequencing technology that may make tests cheaper and faster method than other products on the market or in development. "Platforms such as Helicos' True Single Molecule Sequencing have potential to displace a large part of the $750 million capillary sequencing market," he said. However, he added, the company may struggle to find money to develop and market the system, as well as compete against cheaper products. Derik De Bruin of UBS set a $10 price target for the Cambridge, Mass., company, saying the market for DNA sequencing is growing, but questions remain about Helicos. "As Helicos has yet to demonstrate a fully operational platform, in our view the technology remains largely untested," he said. "Moreover, the company faces competition from larger, more established counterparts with rapidly improving noninvasive genetic sampling systems." Helicos stock has ranged from $8.01 to $9.82 since trading began on May 24, and closed at $8.99 Tuesday. Questions or comments about this story should be directed to the Financial News desk of The Associated Press at (212) 621-7190. |
|
| aus der Diskussion: | Helicos BioSciences Corporation (HLCS) |
| Autor (Datum des Eintrages): | panik (20.07.07 17:38:58) |
| Beitrag: | 2 von 5 (ID:30777364) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |